Please use this identifier to cite or link to this item:
|Title:||Overcoming Barriers to Validation of Non-animal Partial Replacement Methods/Integrated Testing Strategies: The Report of an EPAA-ECVAM Workshop.|
|Authors:||KINSNER-OVASKAINEN Agnieszka; AKKAN Zerin; CASATI Silvia; COECKE Sandra; CORVI Raffaella; DAL NEGRO Gianni; DE BRUIJN Jack; DE SILVA Odile; GRIBALDO Laura; GRIESINGER Claudius; JAWORSKA Joanna; KREYSA JOACHIM; MAXWELL Gavin; MCNAMEE Pauline; PRICE Anna; SCHUBERT Roland; TOSTI LUCA; WORTH Andrew; ZUANG Valerie; PRIETO P.|
|Citation:||ATLA-ALTERNATIVES TO LABORATORY ANIMALS vol. 37 p. 437-444|
|JRC Publication N°:||JRC51533|
|Type:||Articles in Journals|
|Abstract:||The use of Integrated Testing Strategies (ITS) in toxicological hazard identification and characterisation is becoming increasingly common as a method for enabling the integration of diverse types of toxicology data. At present, there are no existing procedures and guidelines for the construction and validation of ITS, so a joint EPAA WG5¿ECVAM workshop was held with the following objectives: a) to investigate the role of ITS and the need for validation of ITS in the different industry sectors (pharmaceuticals, cosmetics, chemicals); b) to formulate a common definition of ITS applicable across different sectors; c) to explore how and when Three Rs methods are used within ITS; and d) to propose a validation rationale for ITS and for alternative methods that are foreseen to be used within ITS. The EPAA provided a platform for comparing experience with ITS across different industry sectors. It became clear that every ITS has to be adapted to the product type, R&D stage, and regulatory context. However, common features of ITS were also identified, and this permitted the formulation of a general definition of ITS in a regulatory context. The definition served as a basis for discussing the needs, rationale and process of formal ITS validation. One of the main conclusions was that a formal validation should not be required, unless the strategy will serve as full replacement of an in vivo study used for regulatory purposes. Finally, several challenges and bottlenecks to the ITS validation were identified, and it was agreed that a roadmap on how to address these barriers would be established by the EPAA partners.|
|JRC Institute:||Institute for Health and Consumer Protection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.